REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL

Objective: To find out the rate of remission of Pre-B Acute Lymphoblastic Leukaemia in children at the end of induction treatment with United Kingdom Acute Lymphoblastic Leukaemia (UKALL) 2011 chemotherapy protocol. Study Design: Prospective observational study. Place and Duration of Study: Pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hafiz Muhammad Murtaza, Tariq Ghafoor, Muhammad Shaheen Iqbal
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	acute lymphoblastic leukaemia induction chemotherapy pre-b acute lymphoblastic leukaemia remission rate united kingdom acute lymphoblastic leukaemia Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/6017fa56f59f4f739266757055a01153
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6017fa56f59f4f739266757055a01153
record_format	dspace
spelling	oai:doaj.org-article:6017fa56f59f4f739266757055a011532021-12-02T16:32:52ZREMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL0030-96482411-884210.51253/pafmj.v71i2.2966https://doaj.org/article/6017fa56f59f4f739266757055a011532021-04-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/2966https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To find out the rate of remission of Pre-B Acute Lymphoblastic Leukaemia in children at the end of induction treatment with United Kingdom Acute Lymphoblastic Leukaemia (UKALL) 2011 chemotherapy protocol. Study Design: Prospective observational study. Place and Duration of Study: Paediatric Oncology Unit, Combined Military Hospital Rawalpindi, from Nov 2017 to Oct 2018. Methodology: Data of newly diagnosed patients of Pre-B Acute lymphoblastic Leukaemia, between 1 and 15 years of age was analysed. Patients were divided into low and high-risk groups and treated with United Kingdom Acute Lymphoblastic Leukaemia 2011 induction chemotherapy on regimens A and B respectively. Bone marrow aspiration was performed at the end of induction therapy (28 days), to document their remission status. Patients having ≤5% of blast cells were categorized to be in remission state and those with >5% blast cells were not considered in a state of remission. Results: A total of 79 patients, 45 (57%) male and 34 (43%) females were enrolled. The mean age was 5.79 ± 3.59 years. Fever (86.1%) and pallor (77.2%) were the most common presentations. Fifty-three (67.1%) patients were treated with regimen A and 26 (32.9%) had regimen B chemotherapy. Febrile neutropenia and myopathy were the most common complications seen in 73 (92.4%) and 54 (71.1%) patients respectively. Eight patients (10.1%) died during induction chemotherapy. Bone marrow aspiration done at the end showed a 100% rate of remission for both regimens A and B. Conclusion: Risk-based treatment of paediatric Acute lymphoblastic Leukaemia............Hafiz Muhammad MurtazaTariq GhafoorMuhammad Shaheen IqbalArmy Medical College Rawalpindiarticleacute lymphoblastic leukaemiainduction chemotherapypre-b acute lymphoblastic leukaemiaremission rateunited kingdom acute lymphoblastic leukaemiaMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss 2, Pp 469-72 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute lymphoblastic leukaemia induction chemotherapy pre-b acute lymphoblastic leukaemia remission rate united kingdom acute lymphoblastic leukaemia Medicine R Medicine (General) R5-920
spellingShingle	acute lymphoblastic leukaemia induction chemotherapy pre-b acute lymphoblastic leukaemia remission rate united kingdom acute lymphoblastic leukaemia Medicine R Medicine (General) R5-920 Hafiz Muhammad Murtaza Tariq Ghafoor Muhammad Shaheen Iqbal REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL
description	Objective: To find out the rate of remission of Pre-B Acute Lymphoblastic Leukaemia in children at the end of induction treatment with United Kingdom Acute Lymphoblastic Leukaemia (UKALL) 2011 chemotherapy protocol. Study Design: Prospective observational study. Place and Duration of Study: Paediatric Oncology Unit, Combined Military Hospital Rawalpindi, from Nov 2017 to Oct 2018. Methodology: Data of newly diagnosed patients of Pre-B Acute lymphoblastic Leukaemia, between 1 and 15 years of age was analysed. Patients were divided into low and high-risk groups and treated with United Kingdom Acute Lymphoblastic Leukaemia 2011 induction chemotherapy on regimens A and B respectively. Bone marrow aspiration was performed at the end of induction therapy (28 days), to document their remission status. Patients having ≤5% of blast cells were categorized to be in remission state and those with >5% blast cells were not considered in a state of remission. Results: A total of 79 patients, 45 (57%) male and 34 (43%) females were enrolled. The mean age was 5.79 ± 3.59 years. Fever (86.1%) and pallor (77.2%) were the most common presentations. Fifty-three (67.1%) patients were treated with regimen A and 26 (32.9%) had regimen B chemotherapy. Febrile neutropenia and myopathy were the most common complications seen in 73 (92.4%) and 54 (71.1%) patients respectively. Eight patients (10.1%) died during induction chemotherapy. Bone marrow aspiration done at the end showed a 100% rate of remission for both regimens A and B. Conclusion: Risk-based treatment of paediatric Acute lymphoblastic Leukaemia............
format	article
author	Hafiz Muhammad Murtaza Tariq Ghafoor Muhammad Shaheen Iqbal
author_facet	Hafiz Muhammad Murtaza Tariq Ghafoor Muhammad Shaheen Iqbal
author_sort	Hafiz Muhammad Murtaza
title	REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL
title_short	REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL
title_full	REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL
title_fullStr	REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL
title_full_unstemmed	REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL
title_sort	remission rate of pre-b all (acute lymphoblastic leukemia) after induction chemotherapy following united kingdom acute lymphoblastic leukaemia 2011 (ukall 2011) trial protocol
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doaj.org/article/6017fa56f59f4f739266757055a01153
work_keys_str_mv	AT hafizmuhammadmurtaza remissionrateofpreballacutelymphoblasticleukemiaafterinductionchemotherapyfollowingunitedkingdomacutelymphoblasticleukaemia2011ukall2011trialprotocol AT tariqghafoor remissionrateofpreballacutelymphoblasticleukemiaafterinductionchemotherapyfollowingunitedkingdomacutelymphoblasticleukaemia2011ukall2011trialprotocol AT muhammadshaheeniqbal remissionrateofpreballacutelymphoblasticleukemiaafterinductionchemotherapyfollowingunitedkingdomacutelymphoblasticleukaemia2011ukall2011trialprotocol
_version_	1718383811507519488

REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL

Ejemplares similares